Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $214.6 million.

  • United Therapeutics' Other Non-Current Liabilities rose 4422.04% to $214.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $214.6 million, marking a year-over-year increase of 4422.04%. This contributed to the annual value of $181.9 million for FY2024, which is 13380.46% up from last year.
  • Latest data reveals that United Therapeutics reported Other Non-Current Liabilities of $214.6 million as of Q3 2025, which was up 4422.04% from $207.3 million recorded in Q2 2025.
  • In the past 5 years, United Therapeutics' Other Non-Current Liabilities ranged from a high of $215.2 million in Q1 2025 and a low of $67.4 million during Q3 2023
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $99.2 million (2021), whereas its average is $120.3 million.
  • Per our database at Business Quant, United Therapeutics' Other Non-Current Liabilities crashed by 3487.92% in 2023 and then skyrocketed by 13380.46% in 2024.
  • Quarter analysis of 5 years shows United Therapeutics' Other Non-Current Liabilities stood at $104.8 million in 2021, then dropped by 0.19% to $104.6 million in 2022, then fell by 25.62% to $77.8 million in 2023, then skyrocketed by 133.8% to $181.9 million in 2024, then increased by 17.98% to $214.6 million in 2025.
  • Its Other Non-Current Liabilities was $214.6 million in Q3 2025, compared to $207.3 million in Q2 2025 and $215.2 million in Q1 2025.